“Discussion: To the best of our knowledge, this pilot study is the first to assess the efficacy and safety of BRH for the treatment of patients with COVID-19. The primary end points and the secondary outcomes did not reach significant difference between the two groups. However, the proportion of remarkable/complete improvement in patients who had chest CTs and the discharge rate within 20 days in the BRH group were 2-fold higher than the control group in value. In addition, the rate of hepatic injury in the BRH group was twofold lower than the control group. These results may suggest that BRH tablets at a dose of 32 mg t.i.d. help to alleviate hepatic or lung injury induced by SARS-CoV-2. No Bromhexine-related adverse drug reactions were found in this study, which indicated 32 mg t.i.d. oral BRH could be safe. A further definitive large-scale clinical trial is feasible and necessary to evaluate its effects and safety.”
© 2020 The Authors. Clinical and Translational Sciencepublished by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.